ABSTRACT
Purpose Making a diagnosis from clinical genomic sequencing requires well-structured phenotypic data to guide genotype interpretation. A patient’s phenotypic features can be documented using the Human Phenotype Ontology (HPO), generating terms used to prioritize genes potentially causing the patient’s disease. We have developed GenomeDiver to provide a user interface for clinicians that allows more effective collaboration with the clinical diagnostic laboratory, with the goal of improving the success of the diagnostic process.
Methods GenomeDiver is designed to prompt reverse phenotyping of patients undergoing genetic testing, enriching the amount and quality of structured phenotype data for the diagnostic laboratory, and helping clinicians to explore and flag diseases potentially causing their patient’s presentation.
Results We show how GenomeDiver communicates the clinician’s informed insights to the diagnostic lab in the form of HPO terms for interpretation of genomic sequencing data. We describe our user-driven design process, the engineering of the software for efficiency, security and portability, and an example of the performance of GenomeDiver using simulated genomic testing data.
Conclusions GenomeDiver is a first step in a new approach to genomic diagnostics that enhances laboratory-clinician interactions, with the goal of directly engaging clinicians to improve the outcome of genomic diagnostic testing.
Competing Interest Statement
NSAH was previously employed at Regeneron Pharmaceuticals and has received an honorarium from Genentech. EEK has received speaker honorariums from Regeneron Pharmaceuticals and Illumina, Inc.
Funding Statement
Research reported in this publication was part of the NYCKidSeq project, supported by the National Human Genome Research Institute and National Institute for Minority Heath and Health Disparities of the National Institutes of Health under Award Number 1U01HG0096108.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This report describes part of the work performed in the NYCKidSeq project. The NYCKidSeq project is approved by the IRBs of the Albert Einstein College of Medicine and the Icahn School of Medicine at Mount Sinai. No human subject information is used in the content of this manuscript.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵a Co-first authors
CONFLICTS OF INTEREST NSAH was previously employed at Regeneron Pharmaceuticals and has received an honorarium from Genentech. EEK has received speaker honorariums from Regeneron Pharmaceuticals and Illumina, Inc.
Data Availability
The manuscript describes software but is not reporting data. The software is available at https://github.com/GenomeDiver/
